Angiopep-2 and activatable cell-penetrating peptide dual-functionalized nanoparticles for systemic glioma-targeting delivery.

Gliomas are hard to treat because of the two barriers involved: the blood-brain barrier and blood-tumor barrier. In this study, a dual-targeting ligand, angiopep-2, and an activatable cell-penetrating peptide (ACP) were functionalized onto nanoparticles for glioma-targeting delivery. The ACP was constructed by conjugating RRRRRRRR (R8) with EEEEEEEE through a matrix metalloproteinase-2 (MMP-2)-sensitive linker. ACP modification effectively enhanced the C6 cellular uptake because of the high expression of MMP-2 on C6 cells. The uptake was inhibited by batimastat, an MMP-2 inhibitor, suggesting that the cell-penetrating property of the ACP was activated by MMP-2. By combining the dual-targeting delivery effect of angiopep-2 and activatable cell-penetrating property of the ACP, the dual-modified nanoparticles (AnACNPs) displayed higher glioma localization than that of single ligand-modified nanoparticles. After loading with docetaxel, a common chemotherapeutic, AnACNPs showed the most favorable antiglioma effect both in vitro and in vivo. In conclusion, a novel drug delivery system was developed for glioma dual targeting and glioma penetrating. The results demonstrated that the system effectively targeted gliomas and provided the most favorable antiglioma effect.

[1]  W. Cavenee,et al.  Host microvasculature influence on tumor vascular morphology and endothelial gene expression. , 1998, The American journal of pathology.

[2]  Chengwen Sun,et al.  Grafting of cell-penetrating peptide to receptor-targeted liposomes improves their transfection efficiency and transport across blood-brain barrier model. , 2012, Journal of pharmaceutical sciences.

[3]  Chen Jiang,et al.  Tumor targeting and microenvironment-responsive nanoparticles for gene delivery. , 2013, Biomaterials.

[4]  Hartwig Wolburg,et al.  The disturbed blood-brain barrier in human glioblastoma. , 2012, Molecular aspects of medicine.

[5]  Z. Qian,et al.  Transferrin/transferrin receptor-mediated drug delivery. , 2002, Medicinal research reviews.

[6]  P. Steeg,et al.  Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer , 2009, Pharmaceutical Research.

[7]  Quanyin Hu,et al.  PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. , 2013, Biomaterials.

[8]  J. Beijnen,et al.  Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. , 2004, European journal of cancer.

[9]  C. Foged,et al.  Cell-penetrating peptides for drug delivery across membrane barriers , 2008, Expert opinion on drug delivery.

[10]  E. Blakely,et al.  Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. , 2000, Cancer research.

[11]  Xiaoling Fang,et al.  Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. , 2011, Biomaterials.

[12]  P. Gaillard,et al.  Targeted delivery across the blood–brain barrier , 2005, Expert opinion on drug delivery.

[13]  K. Lyseng-Williamson,et al.  Docetaxel: a review of its use in metastatic breast cancer. , 2005, Drugs.

[14]  Xin-guo Jiang,et al.  A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. , 2011, Biomaterials.

[15]  Rongqin Huang,et al.  Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma. , 2011, Biomaterials.

[16]  F. Liu,et al.  Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides. , 2013, Biomaterials.

[17]  M. Tanimoto,et al.  Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems , 2012, Nature Communications.

[18]  Wei Lu,et al.  Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[19]  Roger Y Tsien,et al.  Tumor imaging by means of proteolytic activation of cell-penetrating peptides. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Tsien,et al.  Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases , 2010, Proceedings of the National Academy of Sciences.

[21]  Rongqin Huang,et al.  Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Daniel G. Anderson,et al.  Rationally designed tumor-penetrating nanocomplexes. , 2012, ACS nano.

[23]  Erkki Ruoslahti,et al.  De novo design of a tumor-penetrating peptide. , 2013, Cancer research.

[24]  F. Marcucci,et al.  Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. , 2004, Drug discovery today.

[25]  R. Johnston,et al.  © 1999 Cancer Research Campaign Article no. bjoc.1998.0291 , 2022 .

[26]  C. Zhan,et al.  The blood-brain/tumor barriers: challenges and chances for malignant gliomas targeted drug delivery. , 2012, Current pharmaceutical biotechnology.

[27]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[28]  Tianyue Jiang,et al.  Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. , 2012, Biomaterials.

[29]  Yao Qin,et al.  Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes. , 2010, Molecular pharmaceutics.

[30]  Trudeau Me.  Docetaxel: a review of its pharmacology and clinical activity. , 1996 .

[31]  Xin-guo Jiang,et al.  Targeted Delivery of Nano-Therapeutics for Major Disorders of the Central Nervous System , 2013, Pharmaceutical Research.

[32]  Xin-guo Jiang,et al.  Perspectives on brain-targeting drug delivery systems. , 2012, Current pharmaceutical biotechnology.

[33]  T. Terasaki,et al.  Functional characterization of the brain-to-blood efflux clearance of human amyloid-β peptide (1–40) across the rat blood–brain barrier , 2006, Neuroscience Research.

[34]  Jijin Gu,et al.  The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles. , 2012, Biomaterials.

[35]  Amit Modgil,et al.  Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: Biodistribution and transfection. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[36]  B. Ruggeri,et al.  The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice , 2006, Molecular Cancer Therapeutics.

[37]  K. Hosoya,et al.  The blood-brain barrier efflux transporters as a detoxifying system for the brain. , 1999, Advanced drug delivery reviews.

[38]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[39]  A. Rees,et al.  Vector-mediated drug delivery to the brain , 2001, Expert opinion on biological therapy.

[40]  R. Béliveau,et al.  Involvement of the low‐density lipoprotein receptor‐related protein in the transcytosis of the brain delivery vector Angiopep‐2 , 2008, Journal of neurochemistry.

[41]  D. Groothuis,et al.  The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. , 2000, Neuro-oncology.

[42]  Michael C. Park,et al.  Interstitial Docetaxel (Taxotere), Carmustine and Combined Interstitial Therapy: a Novel Treatment for Experimental Malignant Glioma , 2006, Journal of Neuro-Oncology.

[43]  G. Kibria,et al.  Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[44]  G. Tang,et al.  Gene delivery to tumor cells by cationic polymeric nanovectors coupled to folic acid and the cell-penetrating peptide octaarginine. , 2011, Biomaterials.

[45]  Yao Qin,et al.  Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration. , 2011, Molecular pharmaceutics.

[46]  Sagar Agarwal,et al.  Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain , 2011, Expert Reviews in Molecular Medicine.

[47]  Xin-guo Jiang,et al.  Anti-glioma effect and safety of docetaxel-loaded nanoemulsion , 2012, Archives of pharmacal research.

[48]  R. Béliveau,et al.  New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. , 2010, Journal of medicinal chemistry.

[49]  D. Keppler,et al.  ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. , 2005, Cancer research.

[50]  Xin-guo Jiang,et al.  Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. , 2012, Biomaterials.

[51]  Lu Wang,et al.  Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier. , 2012, ACS nano.